Agree completely here that this quarter's 4C was better than anticipated and probably marks a pivotal point in the company's commercialisation journey; a likely inflection point. With the white label opportunity launching shortly too, subsequent quarters should be incrementally better. Don't forget EU/UK launch soon too.
The share price wanted to follow (last Friday) but has settled but that remains an excellent opportunity to consider adding. That's what I've done today.
There would be some point where we will break past these 38-39c levels and then there is little to stop it turning back given the modest market cap and EV. There is reason to believe this could happen any day once the company's profile becomes known to more. The risk reward with Orthocell seems compelling at 38c.
It's about time very very patient investors (like many on here) are rewarded for that patience in abundance.
Ann: Quarterly Activity Report & Appendix 4C, page-51
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $82.68M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $65.71K | 166.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1052 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 354895 | 8 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |